Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma

A California Cancer Consortium trial

George Somlo, Ashkan Lashkari, William Bellamy, Todd M. Zimmerman, Joseph Tuscano, Margaret R. O'Donnell, Ann F. Mohrbacher, Stephen J. Forman, Paul Frankel, Helen X. Chen, James H. Doroshow, David R Gandara

Research output: Contribution to journalArticle

31 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)533-535
Number of pages3
JournalBritish Journal of Haematology
Volume154
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Antineoplastic Combined Chemotherapy Protocols
Thalidomide
Multiple Myeloma
Antineoplastic Agents
Vascular Endothelial Growth Factor A
Monoclonal Antibodies
Recurrence
Neoplasms
Bevacizumab

Keywords

  • Angiogenesis
  • Bevacizumab
  • Multiple myeloma
  • Thalidomide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma : A California Cancer Consortium trial. / Somlo, George; Lashkari, Ashkan; Bellamy, William; Zimmerman, Todd M.; Tuscano, Joseph; O'Donnell, Margaret R.; Mohrbacher, Ann F.; Forman, Stephen J.; Frankel, Paul; Chen, Helen X.; Doroshow, James H.; Gandara, David R.

In: British Journal of Haematology, Vol. 154, No. 4, 08.2011, p. 533-535.

Research output: Contribution to journalArticle

Somlo, George ; Lashkari, Ashkan ; Bellamy, William ; Zimmerman, Todd M. ; Tuscano, Joseph ; O'Donnell, Margaret R. ; Mohrbacher, Ann F. ; Forman, Stephen J. ; Frankel, Paul ; Chen, Helen X. ; Doroshow, James H. ; Gandara, David R. / Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma : A California Cancer Consortium trial. In: British Journal of Haematology. 2011 ; Vol. 154, No. 4. pp. 533-535.
@article{9a064c793796494898844c3a81c1b6e8,
title = "Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial",
keywords = "Angiogenesis, Bevacizumab, Multiple myeloma, Thalidomide, Vascular endothelial growth factor",
author = "George Somlo and Ashkan Lashkari and William Bellamy and Zimmerman, {Todd M.} and Joseph Tuscano and O'Donnell, {Margaret R.} and Mohrbacher, {Ann F.} and Forman, {Stephen J.} and Paul Frankel and Chen, {Helen X.} and Doroshow, {James H.} and Gandara, {David R}",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2141.2011.08623.x",
language = "English (US)",
volume = "154",
pages = "533--535",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma

T2 - A California Cancer Consortium trial

AU - Somlo, George

AU - Lashkari, Ashkan

AU - Bellamy, William

AU - Zimmerman, Todd M.

AU - Tuscano, Joseph

AU - O'Donnell, Margaret R.

AU - Mohrbacher, Ann F.

AU - Forman, Stephen J.

AU - Frankel, Paul

AU - Chen, Helen X.

AU - Doroshow, James H.

AU - Gandara, David R

PY - 2011/8

Y1 - 2011/8

KW - Angiogenesis

KW - Bevacizumab

KW - Multiple myeloma

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=79960846565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960846565&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08623.x

DO - 10.1111/j.1365-2141.2011.08623.x

M3 - Article

VL - 154

SP - 533

EP - 535

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -